The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Phepranon     2-diethylamino-1-phenyl- propan-1-one

Synonyms: Regenon, Tenuate, Tepanil, Amfepramon, Anorex, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Amfepramone

 

Psychiatry related information on Amfepramone

 

High impact information on Amfepramone

 

Chemical compound and disease context of Amfepramone

 

Biological context of Amfepramone

 

Anatomical context of Amfepramone

  • The objective and timing of drug disposition studies, appendix III. Diethylpropion and its metabolites in the blood plasma of the human after subcutaneous and oral administration [21].
  • Following 11 days of treatment with diethylpropion, amphetamine or mazindol, there was a significant increase in purine nucleotide (GDP) binding to mitochondria only in the amphetamine-treated animals [22].
  • Toxicological analysis of these droplets revealed the presence of thyroid extract and diethylpropione, an amphetamine-like noradrenergic anorectic agent banned in Belgium [23].
 

Associations of Amfepramone with other chemical compounds

 

Gene context of Amfepramone

 

Analytical, diagnostic and therapeutic context of Amfepramone

References

  1. Treatment of obesity: cost-benefit assessment of behavioral therapy, placebo, and two anorectic drugs. Dahms, W.T., Molitch, M.E., Bray, G.A., Greenway, F.L., Atkinson, R.L., Hamilton, K. Am. J. Clin. Nutr. (1978) [Pubmed]
  2. An experimental model for assessing effects of anorectics on spontaneous food intake of obese subjects. Porikos, K.P., Sullivan, A.C., Mc Ghee, B., Van Itallie, T.B. Clin. Pharmacol. Ther. (1980) [Pubmed]
  3. Activity of anorectic drugs (Amphetamine), amfepramone and UP 507-O4) on two models of obesity in animals [proceedings]. Dumeur, G., Hüe, B., Lwoff, J.M., Mouries, M.A., Tremblay, D. Br. J. Pharmacol. (1976) [Pubmed]
  4. High prevalence of fenfluramine-related aortic regurgitation in women with end-stage renal disease secondary to Chinese herb nephropathy. Unger, P., Nortier, J., Muniz Martinez, M.C., Plein, D., Vandenbossche, J.L., Vereerstraeten, P., Vanherweghem, J.L. Nephrol. Dial. Transplant. (2003) [Pubmed]
  5. Neurotoxicity of diethylpropion: neurochemical and behavioral findings in rats. Galvan-Arzate, S., Santamaria, A. Ann. N. Y. Acad. Sci. (2002) [Pubmed]
  6. Effects of amphetamine, dexfenfluramine, diazepam, and other pharmacological and dietary manipulations on food "seeking" and "taking" behavior in non-human primates. Foltin, R.W. Psychopharmacology (Berl.) (2001) [Pubmed]
  7. Serotonin1A-receptor antagonism blocks psychostimulant properties of diethylpropion in marmosets (Callithrix penicillata). Mello, E.L., Maior, R.S., Carey, R.J., Huston, J.P., Tomaz, C., Müller, C.P. Eur. J. Pharmacol. (2005) [Pubmed]
  8. The Copenhagen PRODI project: preliminary results. Quaade, F., Hyldstrup, L., Andersen, T. International journal of obesity. (1981) [Pubmed]
  9. Lack of neurotoxic effect of diethylpropion in crack-cocaine abusers. Ollo, C., Alim, T.N., Rosse, R.B., Lindquist, T., Green, T., Gillis, T., Ricci, J., Khan, M., Deutsch, S.I. Clinical neuropharmacology. (1996) [Pubmed]
  10. Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells. Lee, K., Khan, R.N., Rowe, I.C., Ozanne, S.E., Hall, A.C., Papadakis, E., Hales, C.N., Ashford, M.L. Mol. Pharmacol. (1996) [Pubmed]
  11. The contribution of increased thermogenesis to the effect of anorectic drugs on body composition in mice. Arch, J.R. Am. J. Clin. Nutr. (1981) [Pubmed]
  12. Safety of drug therapies used for weight loss and treatment of obesity. Ioannides-Demos, L.L., Proietto, J., Tonkin, A.M., McNeil, J.J. Drug safety : an international journal of medical toxicology and drug experience. (2006) [Pubmed]
  13. Effects of intravenous cocaine, diethylpropion, d-amphetamine and perphenazine on responding maintained by food delivery and shock avoidance in rhesus monkeys. Johanson, C.E. J. Pharmacol. Exp. Ther. (1978) [Pubmed]
  14. Controlled-release diethylpropion hydrochloride used in a program for weight reduction. Parsons, W.B. Clinical therapeutics. (1981) [Pubmed]
  15. Chinese herbs nephropathy-associated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats. Cosyns, J.P., Goebbels, R.M., Liberton, V., Schmeiser, H.H., Bieler, C.A., Bernard, A.M. Arch. Toxicol. (1998) [Pubmed]
  16. Ventricular arrhythmias complicating weight reduction therapy in a patient with a prolonged QT interval. O'Keefe, J.C., Butrous, G.S., Dymond, D.S., Littlejohns, P., Peters, N., Banim, S.O. Postgraduate medical journal. (1985) [Pubmed]
  17. Influence of pH on hydrolytic decomposition of diethylpropion hydrochloride: stability studies on drug substance and tablets using high-performance liquid chromatography. Walters, S.M. Journal of pharmaceutical sciences. (1980) [Pubmed]
  18. Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Abramowicz, M.J., Van Haecke, P., Demedts, M., Delcroix, M. Eur. Respir. J. (2003) [Pubmed]
  19. Double blind evaluation of long acting diethylpropion hydrochloride in obese patients from a general practice. Carney, D.E., Tweddell, E.D. Med. J. Aust. (1975) [Pubmed]
  20. Effect of (3',4'-dichloro-2(2-imidazolin-2-yl-thio)-acetophenone hydrobromide) (DITA) on pulmonary and systemic arterial blood pressure: a comparison with diethylpropion. Abdallah, A.H., Roby, D.M. J. Pharm. Pharmacol. (1977) [Pubmed]
  21. The objective and timing of drug disposition studies, appendix III. Diethylpropion and its metabolites in the blood plasma of the human after subcutaneous and oral administration. Wright, G.J., Lang, J.F., Lemieux, R.E., Goodfriend, M.J. Drug Metab. Rev. (1975) [Pubmed]
  22. Effect of mazindol, d-amphetamine and diethylpropion on purine nucleotide binding to brown adipose tissue. Lupien, J.R., Bray, G.A. Pharmacol. Biochem. Behav. (1986) [Pubmed]
  23. Homeopathic products, not as innocent and safe as they seem? A case report. Mortelmans, L.J., Biesemans, L., Van Rossom, P. European journal of emergency medicine : official journal of the European Society for Emergency Medicine. (2004) [Pubmed]
  24. In vitro adsorption-desorption of phenethylamines and phenylimidazoles by a bentonite and a resin. Stul, M.S., Vliers, D.P., Uytterhoven, J.B. Journal of pharmaceutical sciences. (1984) [Pubmed]
  25. A double-blind controlled study of the use of diethylpropion hydrochloride (Tenuate) in obese patients in a rural practice. Elliott, B.J. N. Z. Med. J. (1978) [Pubmed]
  26. Comparison of saliva and urine samples in thin-layer chromatographic detection of central nervous stimulants. Vapaatalo, H., Kärkäinen, S., Senius, K.E. International journal of clinical pharmacology research. (1984) [Pubmed]
  27. The assessment of the dopaminergic tonus by urinary determinations of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in normal, obese and GH-deficient short children. Popa, M., Stefănescu, A.M., Dumitriu, L., Simionescu, L., Giurcăneanu, M. Endocrinologie. (1988) [Pubmed]
  28. Amfepramone does not cause primary pulmonary hypertension. Di Sacco, G. Eur. Respir. J. (2004) [Pubmed]
  29. High-performance liquid chromatographic determination of diethylpropion hydrochloride in tablets: isolation and identification of two decomposition products. Walters, M.J., Walters, S.M. Journal of pharmaceutical sciences. (1977) [Pubmed]
  30. Enantioseparation of amfepramone (rac-diethylpropion): preparative separation of the enantiomers and enantioselective analysis. Mey, B., Paulus, H., Lamparter, E., Blaschke, G. Chirality. (1999) [Pubmed]
  31. Evaluation of the percutaneous absorption and metabolism of some aminopropiophenones. Markantonis, S.L., Kyroudis, A., Beckett, A.H. J. Pharm. Pharmacol. (1986) [Pubmed]
  32. Simultaneous determination of amfepramon and its two major metabolites in biological fluids by gas liquid chromatography. Dangor, C.M., Beckett, A.H., Veltman, A.M. Arzneimittel-Forschung. (1986) [Pubmed]
  33. Cardiovascular effects of amphepramone. Safta, L., Cuparencu, B. Physiologie. (1978) [Pubmed]
 
WikiGenes - Universities